The PDUFA date of February 28, 2027 is the next major catalyst. Monitor for any FDA advisory committee meeting announcements or complete response letter risks. The company's cash position of $236.7M appears sufficient to fund operations through the PDUFA date and initial launch preparations.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $156.85entry
- T+1 · 11d ago +12.16%α +11.85% · $175.92
- T+5 · 5d ago −2.34%α −5.63% · $153.18
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Palvella reported Q3 2026 results with a net loss of $24.6M ($1.70/share), wider than the $11.3M loss in Q3 2025, as R&D and G&A expenses increased. The key event is the FDA's acceptance of the NDA for QTORIN rapamycin in microcystic lymphatic malformations with Priority Review and a PDUFA date of February 28, 2027, bringing the company closer to a potential first FDA-approved therapy for this indication.
Key Financial Metrics
Key Facts
- FDA accepted NDA for QTORIN rapamycin for microcystic lymphatic malformations with Priority Review; PDUFA target action date February 28, 2027
- Cash, cash equivalents and short-term investments of $236.7 million as of September 30, 2026
- Net loss of $24.6 million ($1.70 per share) for Q3 2026, compared to net loss of $11.3 million ($1.03 per share) for Q3 2025
- Research and development expenses of $10.8 million for Q3 2026, up from $6.5 million in Q3 2025
- General and administrative expenses of $11.9 million for Q3 2026, up from $3.6 million in Q3 2025
- Phase 3 trial initiation for cutaneous venous malformations on track for Q4 2026
- Phase 2 trial initiation for DSAP expected in Q4 2026
- Two additional pipeline programs anticipated to be announced by year-end 2026
Financial Impact
Net loss increased to $24.6M in Q3 2026 from $11.3M in Q3 2025, driven by higher R&D and G&A costs as the company advanced its NDA submission and built commercial infrastructure. Cash burn is expected to continue as the company prepares for a potential launch in 1H 2027.
Risk Factors
- FDA may issue a complete response letter or require additional clinical data before approval
- Commercial launch execution risk if approved, as Palvella has no prior commercial experience
- Increasing operating losses as the company scales up commercial and medical affairs teams
- Pipeline programs are still in early stages and may not succeed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-448594 |
| Document: pvla-20261105.htm | 0001193125-26-448594 |
| Document: pvla-ex99_2.htm | 0001193125-26-448594 |
| Document: 0001193125-26-448594-index-headers.html | 0001193125-26-448594 |
| Document: 0001193125-26-448594-index.html | 0001193125-26-448594 |
| Document: 0001193125-26-448594.txt | 0001193125-26-448594 |
| 8-K Data (Synthetic) | 0001193125-26-448594 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Viewing Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers